Agomab Therapeutics NV

For the period ended Dec 31, 2025. Filed Apr 23, 2026.

About this filing

The yearly report of a company based outside the US. It covers much of what a 10-K does, and may follow accounting rules other than US ones.

FY2025 · Filed Apr 23, 2026

AGMB$7.64+9.5%Stored close · as of Nov 6, 2026

Contents

We refer to note 26 of our financial statements.

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.